Table 4. Univariate and multivariate analyses of the prognostic influence of clinicopathological factors on overall survival.

Clinicopathological features	median OS (month)	Univariate analyses					Multivariate analyses
		OS (%)			χ2	P	HR	95.0% CI for HR		P
		1year	3year	5year				low	high
ECOG performance status
(0,1)	72.00	90.80	65.52	24.14	0.019	0.891
(2,3)	72.00	95.24	64.28	35.71
Age (y)
<50	72.00	94.55	69.09	29.09	2.375	0.123
≥50	70.89	90.54	62.16	27.03
Stage
II	72.00	96.72	68.85	26.23	3.210	0.073
III	72.00	88.24	61.76	29.41
Lymph nodes metastases
No	72.00	100.00	85.71	48.57	31.257	0.000	0.869	0.411	1.835	0.712
Yes	32.77	84.75	40.68	3.39
Differentiation
Well-moderate	72.00	93.55	58.06	25.81	0.028	0.867
Poor	72.00	91.04	71.64	29.85
Tumor size
≥5.7cm	53.24	87.95	48.19	16.87	23.076	0.000	2.646	0.987	7.092	0.053
<5.7cm	72.00	100.00	95.65	47.83
SCC-ag level (ng/ml)
<2	70.99	97.92	62.50	31.25	1.101	0.577
2-10	72.00	84.91	66.04	24.53
>10	72.00	96.43	67.86	28.57
Hb level (g/dl)
<10	72.00	91.49	71.28	29.79	6.466	0.004	0.704	0.389	1.276	0.247
≥10	48.95	94.29	48.57	22.86
Treatment
Radiation	72.00	90.54	62.16	22.97	0.009	0.925
Concurrent Chemoradiation	72.00	94.55	69.09	34.55
AURKA IHC
High	38.44	86.30	42.47	5.48	44.402	0.000	9.091	2.597	32.258	0.001
Low	72.00	100.00	94.64	57.14